JNTX-102

Generic Name: JNTX-102

Clinical Trials

Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis and Sepsis Associated Acute Kidney Injury

Not Applicable

Not yet recruiting

Conditions: Liver Cirrhosis
Acute Kidney Injury

Interventions: Other: Standard Medical Treatment
Biological: Albumin

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 100

Registration Number: NCT06809088

Locations: 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India

The Intensive Care Platform Trial

Phase 4

Not yet recruiting

Conditions: Intensive Care Patients
Intensive Care Unit Patients
Critical Illness

Interventions: Drug: Albumin
Other: No albumin

First Posted Date: 2024-10-31

Last Posted Date: 2024-10-31

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 10000

Registration Number: NCT06667999

Locations: 🇩🇰
Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia

Not Applicable

Completed

Conditions: Pregnancy
Cesarean Delivery
Spinal Anesthesia Induced Hypotension
Cardiac Output Measurement
Volume Status

Interventions: Device: Transthoracic Echocardiography
Drug: Ringer lactate 1000 ml
Drug: Albumin
Drug: Ringer lactate 750 ml

First Posted Date: 2024-10-23

Last Posted Date: 2025-05-21

Lead Sponsor: Sameh Fathy

Target Recruit Count: 162

Registration Number: NCT06654687

Locations: 🇪🇬
Mansoura University, Mansoura, Egypt

Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis.

Not Applicable

Not yet recruiting

Conditions: Decompensated Cirrhosis

Interventions: Drug: Midodrine
Drug: Albumin
Other: Standard of Care

First Posted Date: 2024-02-07

Last Posted Date: 2024-02-07

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 100

Registration Number: NCT06245590

Locations: 🇮🇳
Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India
🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

High Dose Albumin in Refractory Ascites

Phase 2

Recruiting

Conditions: Ascites

Interventions: Drug: Albumin

First Posted Date: 2023-05-22

Last Posted Date: 2024-08-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 100

Registration Number: NCT05867602

Locations: 🇺🇸
Baylor St' Lukes Medical center, Houston, Texas, United States

Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients

Phase 4

Not yet recruiting

Conditions: Shock

Interventions: Drug: Compound sodium acetate ringer injection
Drug: Albumin

First Posted Date: 2022-07-19

Last Posted Date: 2022-07-19

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05463471

Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension

Recruiting

Conditions: Acute on Chronic Liver Failure
Cirrhosis, Liver
Sepsis

Interventions: Drug: Albumin

First Posted Date: 2021-09-28

Last Posted Date: 2024-04-25

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 300

Registration Number: NCT05059795

Locations: 🇮🇳
PGIMER, Chandigarh, India
🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India

Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

Completed

Conditions: Burns Shock

Interventions: Drug: Albumin

First Posted Date: 2021-06-16

Last Posted Date: 2021-06-16

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 364

Registration Number: NCT04928859

Midodrine and Albumin in Patients With Refractory Ascites

Phase 3

Conditions: Refractory Ascites

Interventions: Drug: Albumin
Drug: Standard medical therapy (SMT)
Drug: Midodrine

First Posted Date: 2020-11-09

Last Posted Date: 2020-11-09

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 114

Registration Number: NCT04621617

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Phase 2

Withdrawn

Conditions: Immune-Mediated Necrotizing Myopathy

Interventions: Drug: Gamunex-C
Drug: Albumin

First Posted Date: 2020-06-29

Last Posted Date: 2022-10-24

Lead Sponsor: University of Washington

Registration Number: NCT04450654

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy